---
title: "Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence"
description: "Formulary evidence on Zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy: Clinical evidence. Covers DELIVER, FORZETTO, PROMOVI, 22-ANGR-120, and TTE. 80 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 DELIVER

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Main safety objective

> “To evaluate the safety and tolerability of multiple IV doses”

Source: [EU Clinical Trials Register 2021-005478-24](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005478-24/BE)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Participating U.S. site and study start

> “La Jolla California 92037 United States”
> “August 2022”

Source: [University of California San Diego (2026)](https://clinicaltrials.ucsd.edu/trial/NCT05524883)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### DELIVER: design

> “DELIVER is a global, randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial”

Source: [Dyne Therapeutics clinical trials page](https://www.dyne-tx.com/clinical-trials/)

<a id="topic-3.1.1.3-2"></a>

###### Original placebo-controlled and extension periods

> “a MAD/placebo-controlled period (24 weeks), an open-label extension period (OLE, 24 weeks), and a long-term extension (LTE) period (96 weeks; Figure 3).”

Source: [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Updated long-term extension duration

> “288 weeks”

Source: [University of California San Diego (2026)](https://clinicaltrials.ucsd.edu/trial/NCT05524883)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### DELIVER: age eligibility

> “Age 4 to 16 years inclusive”

Source: [DMD Hub](https://dmdhub.org/trials/dyne-therapeutics-dyne-251/)

<a id="topic-3.1.1.4-2"></a>

###### DELIVER: concomitant glucocorticoid requirement

> “a stable dosage of glucocorticoids for ≥12 weeks”

Source: [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf)

<a id="topic-3.1.1.4-3"></a>

###### DELIVER: mutation requirement

> “confirmed DMD mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping.”

Source: [DMD Hub](https://dmdhub.org/trials/dyne-therapeutics-dyne-251/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Registrational dose and schedule

> “Proposed dosing regimen of 20 mg/kg administered intravenously once every 4 weeks (Q4W)”

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Dystrophin Expression as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### DELIVER: primary endpoints

> “Primary endpoints include safety, tolerability, and change from baseline in dystrophin levels in muscle measured by Western blot.”

Source: [Flanigan et al. (2024)](https://www.mdaconference.org/abstract-library/initial-data-from-the-deliver-trial-of-dyne-251-in-males-with-dmd-mutations-amenable-to-exon-51-skipping/)

<a id="topic-3.1.1.6.1-2"></a>

###### Regulatory use of dystrophin

> “Submission for Accelerated Approval based on dystrophin as a surrogate endpoint”

Source: [Dyne Therapeutics Biologics License Application acceptance announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license)

<a id="topic-3.1.1.6.1-3"></a>

###### Outcome-instrument evidence: SV95C clinical meaningfulness

> “Distribution- and anchor-based approaches revealed a change of −0.10 to −0.20 m/s as clinically meaningful.”

Source: [Servais et al. (2024)](https://www.nature.com/articles/s41598-024-80177-9)

<a id="topic-3.1.1.6.1-4"></a>

###### Outcome-instrument validation: North Star Ambulatory Assessment meaningful change

> “Anchored on the 6MWD, the MCID for NSAA was estimated as 3.5 points.”

Source: [Ayyar Gupta et al. (2023)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0283669)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### DELIVER: registrational expansion cohort enrollment

> “enrollment of 32 patients in the REC”

Source: [Dyne Therapeutics third quarter 2025 results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2025-financial-results)

<a id="topic-3.1.1.7.1-2"></a>

###### DELIVER: registrational expansion cohort allocation

| Group | Direct quotation |
| --- | --- |
| Z-rostudirsen | “24 participants” |
| Placebo | “8” |

Source: [Dyne Therapeutics DELIVER topline results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12)

<a id="topic-3.1.1.7.1-3"></a>

###### DELIVER: functional-endpoint statistical power

> “functional assessments, although the REC is not powered to demonstrate statistical significance on these endpoints.”

Source: [Dyne Therapeutics third quarter 2025 results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2025-financial-results)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### DELIVER registrational expansion cohort: functional analysis

> “Post-hoc analysis”

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Functional hypothesis-testing plan

> “prespecified statistical analysis plan did not include formal hypothesis testing for any functional endpoint”

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### DELIVER registrational expansion cohort: six-month functional analysis populations

| Analysis population | Direct quotation |
| --- | --- |
| Placebo | “Placebo: n=18”; “(REC+MAD)” |
| Z-rostudirsen | “Z-rostudirsen: n=21”; “(REC)” |

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Study withdrawals caused by treatment-emergent adverse events: all z-rostudirsen doses

| Disposition measure | Quoted result |
| --- | --- |
| Exposed participants across all study periods | “N=85” |
| TEAEs leading to study withdrawal | “0” |

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics: pooled MAD and REC placebo versus active REC

| Characteristic | Pooled placebo | Z-rostudirsen REC |
| --- | --- | --- |
| Age, years, mean (SD) | “8.2 (2.5)” | “7.8 (3.6)” |
| Ambulant participants, n (%) | “19 (79.2)” | “21 (87.5)” |

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### DELIVER registrational expansion cohort: six-month dystrophin results

| Measure | Direct quotation |
| --- | --- |
| Mean absolute dystrophin, muscle-content adjusted | “5.46% of normal” |
| Muscle-content-adjusted dystrophin, comparison with baseline | “p<0.0001” |
| Mean absolute dystrophin, unadjusted | “2.87% of normal (p < 0.0001)” |

Source: [Dyne Therapeutics DELIVER topline results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12)

<a id="topic-3.1.1.8.3-2"></a>

###### DELIVER registrational expansion cohort: six-month functional results

| Endpoint | Reported difference | Reported statistical result |
| --- | --- | --- |
| “TTR velocity” | “∆0.04 rise/sec” | “(nominal p<0.05)” |
| “10MWR velocity” | “∆0.2 m/sec” | “(nominal p<0.05)” |
| “NSAA” | “∆2.1 points” | “(nominal p=0.0894)” |

Source: [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### DELIVER: earlier multiple-ascending-dose results

> “patients treated with 20 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin expression of 8.72% of normal (adjusted for muscle content).”

Source: [Dyne Therapeutics DELIVER long-term clinical data announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12)

<a id="topic-3.1.1.8.3-4"></a>

###### DELIVER: optional long-term biopsy results, muscle-content-adjusted dystrophin

> “(67-104 weeks)”
> “18.33% of normal (n=4) as compared to 1.47% at baseline (n=3).”

Source: [Dyne Therapeutics first quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2026-financial-results)

<a id="topic-3.1.1.8.3-5"></a>

###### DELIVER: cardiopulmonary analyses

> “New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history”

Source: [Dyne Therapeutics cardiopulmonary results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-results/)

Additional sources: [Shieh et al. (2025)](https://www.neurology.org/doi/abs/10.1212/WNL.0000000000211198); [Guglieri et al. (2025b)](https://www.nmd-journal.com/article/S0960-8966%2825%2900359-1/fulltext)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### DELIVER: safety and efficacy poster

> “970 doses of study drug administered to date over a period of 77.1 patient-years of follow-up”

Source: [Phan et al. (2025)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2025_MDA_DELIVER_Poster.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### DELIVER safety: registrational expansion cohort

> “No related serious TEAEs were observed in the registrational expansion cohort (REC).”

Source: [Dyne Therapeutics first quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2026-financial-results)

<a id="topic-3.1.1.8.5-3"></a>

###### DELIVER safety: open-label and long-term extensions

| Safety element | Direct quotation |
| --- | --- |
| Classification | “related serious TEAEs” |
| Participants | “two participants” |
| Events | “malaise and/or pyrexia (fever)” |
| Recovery | “fully recovered” |

Source: [Dyne Therapeutics DELIVER topline results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12)

<a id="topic-3.1.1.8.5-4"></a>

###### DELIVER safety: higher-dose findings

> “two participants at the 40 mg/kg dose level with events potentially related to study drug and both participants have recovered.”

Source: [Dyne Therapeutics new DELIVER clinical data announcement (2024)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-clinical-data-phase-12-deliver)

<a id="topic-3.1.1.8.5-5"></a>

###### DELIVER safety: higher-dose event details

> “40 mg/kg Q4W”
> “Acute kidney injury; thrombocytopenia.”
> “Pancytopenia.”

Source: [Guglieri et al. (2025c)](https://www.dyne-tx.com/wp-content/uploads/Guglieri_2025_WMS_DELIVER%20Poster.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The 32-participant registrational expansion cohort was not powered for statistically significant functional comparisons. The reported functional analysis was post hoc, combined placebo participants from the registrational and multiple-ascending-dose cohorts, and reported nominal p values; the prespecified plan did not include formal hypothesis testing of functional endpoints. Optional late biopsies involved four participants, compared with three baseline samples. Cardiopulmonary findings were compared with natural history and reflected mixed dose exposures, not continuous 20 mg/kg treatment throughout follow-up. Observational associations involving residual dystrophin should not be treated as direct proof of benefit from therapeutically restored dystrophin.

Source: [Dyne Therapeutics third quarter 2025 results announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2025-financial-results); [Flanigan et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Flanigan_2026_MDA_DELIVER_REC_Poster.pdf); [Dyne Therapeutics first quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2026-financial-results); [Dyne Therapeutics cardiopulmonary results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-results/); [Laverty et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Laverty_2026_MDA%20_DELIVER_LTE_Poster.pdf); [Hoffman and Clemens (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8251539/)

<a id="topic-3.1.1.9-2"></a>

###### DELIVER: cardiopulmonary exposure limitation

> “The outcomes represent a mixture of exposures and do not reflect the effect of maintaining 20 mg/kg for the entire treatment duration”

Source: [Laverty et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Laverty_2026_MDA%20_DELIVER_LTE_Poster.pdf)

<a id="topic-3.1.1.9-3"></a>

###### Residual dystrophin: letter to the editor

> “The study results, although interesting for a genotype–phenotype correlation, should not be extrapolated to being informative in a dystrophin‐restoring therapeutic context.”

Source: [Hoffman and Clemens (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8251539/)

<a id="heading-3.1.2"></a>

#### 3.1.2 FORZETTO

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Confirmatory study objective

> “assess the efficacy, safety, and tolerability”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Trial-initiation announcement date

> “May 20, 2026”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Confirmatory trial design

> “global, randomized, placebo-controlled, double-blind, confirmatory Phase 3 trial”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="topic-3.1.2.3-2"></a>

###### FORZETTO: allocation

> “randomized 1:1”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="topic-3.1.2.3-3"></a>

###### FORZETTO: extension

| Study element | Direct quotation |
| --- | --- |
| Open-label long-term extension | “96 weeks” |

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### FORZETTO: population

| Study element | Direct quotation |
| --- | --- |
| Population | “Ambulatory males aged 4–18 years” |

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="topic-3.1.2.4-2"></a>

###### Glucocorticoid stability requirement

> “glucocorticoids for at least 24 weeks”

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="topic-3.1.2.4-3"></a>

###### Rise-from-floor threshold at both screening assessments

> “<10 seconds”

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Investigational dose and schedule

> “20 mg/kg Q4W”

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Rise-from-Floor Velocity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### FORZETTO: primary endpoint

> “Primary endpoint is rise from floor (RFF) velocity”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="topic-3.1.2.6.1-2"></a>

###### FORZETTO: endpoints

| Study element | Direct quotation |
| --- | --- |
| Primary endpoint | “Change from baseline in RFF velocity at Week 73” |
| Selected secondary endpoint | “SV95C” |
| Selected secondary endpoint | “NSAA total score” |
| Selected secondary endpoint | “10MWR velocity” |
| Selected secondary endpoint | “4SC velocity” |

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="topic-3.1.2.6.1-3"></a>

###### Clinical relevance of rise-from-floor velocity

> “a clinically meaningful measure of muscle strength and motor coordination”

Source: [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### FORZETTO: planned enrollment and follow-up

> “72-week trial will enroll approximately 90 participants; first site now open for enrollment”

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The available evidence describes the design of an approximately 90-participant confirmatory trial, not completed efficacy or safety results. The population is restricted to ambulatory males aged 4–18 years, with a screening rise-from-floor threshold below 10 seconds and stable glucocorticoids for at least 24 weeks. Therefore, the planned population does not directly address non-ambulatory participants. The primary assessment is at Week 73, following the stated 72-week treatment period.

Source: [Dyne Therapeutics FORZETTO initiation announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-initiation-phase-3-forzetto-trial-z); [Naylor et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Naylor_2026_ICNMD_FORZETTO.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 PROMOVI

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Domains evaluated

> “efficacy and safety”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

Additional sources: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Trial design

> “phase 3, multicenter, open-label”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Ambulatory participant age range

> “7-16 years”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Eteplirsen regimen

> “30 mg/kg/week intravenously for 96 weeks”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Six-Minute Walk Test Distance as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint: change from baseline to week 96

> “6MWT distance”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Participants enrolled

| Cohort | Quoted count |
| --- | --- |
| Eteplirsen | “79” |
| Untreated | “30” |

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

Additional sources: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Completion of follow-up

| Cohort | Quoted completion count |
| --- | --- |
| Eteplirsen at 96 weeks | “78/79” |
| Untreated | “15/30” |

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Eteplirsen baseline age

| Characteristic | Quoted result |
| --- | --- |
| Age, years, mean and standard deviation | “9.1±2.0” |

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Eteplirsen PROMOVI trial: week 96

> “dystrophin protein (7-fold) versus baseline.”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Most frequent treatment-related adverse events

> “headache and vomiting”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

PROMOVI was open label and included 79 eteplirsen-treated and 30 untreated participants. Completion was reported for 78 of 79 treated participants and 15 of 30 untreated participants. The investigators considered the untreated cohort inappropriate for comparison because of genotype-related differences in clinical trajectory. The reported seven-fold dystrophin increase is relative to baseline and is not interchangeable with an absolute percentage of normal dystrophin. This was not a direct comparison with z-rostudirsen.

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="topic-3.1.3.9-2"></a>

###### Eteplirsen PROMOVI trial: untreated comparison cohort

> “this cohort was considered an inappropriate control group because of genotype-driven differences in clinical trajectory.”

Source: [McDonald et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8673535/)

<a id="heading-3.1.4"></a>

#### 3.1.4 22-ANGR-120

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Survival outcome evaluated

> “overall survival”

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

Additional sources: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Treated-cohort data source

> “administrative information”

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Treated study population

> “eteplirsen-treated US patients”

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Observed treatment

> “eteplirsen”

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Overall Survival as a Clinical Endpoint

Not applicable.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Primary comparison populations

| Cohort | Quoted count |
| --- | --- |
| Eteplirsen | “579” |
| Natural-history controls | “1224” |

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### External-control construction

> “reproduced patient-level data”

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Treated-cohort disposition

| Status | Quoted result |
| --- | --- |
| Died, n (%) | “29 (5.0)” |
| Censored, n (%) | “550 (95.0)” |

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Age at treatment initiation

| Characteristic | Quoted result |
| --- | --- |
| Age, years, mean and standard deviation | “11.9 ± 6.4” |

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Eteplirsen versus natural-history survival association

| Measure | Quoted result |
| --- | --- |
| Median survival age with eteplirsen, years | “32.8” |
| Median survival age in natural-history cohorts, years | “27.4” |
| Hazard ratio | “0.34” |
| 95% confidence interval | “0.23–0.50” |

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The study compared administrative data for 579 eteplirsen-treated participants with reconstructed patient-level information for 1,224 natural-history controls. It was not a randomized comparison. Consequently, the reported survival association cannot establish an unbiased causal treatment effect or a comparison with z-rostudirsen. Reconstruction of external controls and differences between data sources limit comparability.

Source: [Iff et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28075)

Additional sources: [Burnette (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28107)

<a id="heading-3.1.5"></a>

#### 3.1.5 TTE

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Mortality outcome

> “all-cause mortality”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### U.S. claims observation period

> “January 2016–September 2024”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Underlying data design

> “Retrospective claims data”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Participant sex criterion

> “male sex”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Observed treatment strategies

| Strategy | Quoted group label |
| --- | --- |
| Exon-skipping therapy plus glucocorticoids | “PMO + GCs” |
| Glucocorticoids without a PMO | “GCs-only” |

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using All-Cause Mortality as a Clinical Endpoint

Not applicable.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### First emulated trial populations

| Cohort | Quoted count |
| --- | --- |
| PMO initiators | “112” |
| Glucocorticoid-only initiators | “2916” |

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Confounding and censoring adjustment

> “inverse probability of treatment and censoring weighting”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

Additional sources: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

Additional sources: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Eteplirsen, casimersen, and golodirsen survival analysis: 48 pooled emulated trials

> “hazard ratio 0.303; 95% confidence interval 0.119–0.769; P = 0.012”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="topic-3.1.5.8.3-2"></a>

###### Eteplirsen, casimersen, and golodirsen survival analysis: 66 pooled emulated trials

> “HR 0.477; 95% CI 0.194–1.169; P = 0.105”

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This retrospective claims analysis pooled eteplirsen, casimersen, and golodirsen, rather than evaluating z-rostudirsen. Weighting addressed measured treatment-selection and censoring factors but does not make the comparison randomized. The 48-trial pooled estimate was HR 0.303 (95% CI 0.119–0.769), whereas the 66-trial estimate was HR 0.477 (95% CI 0.194–1.169). The latter interval includes 1. Results therefore depend on the pooled analysis and do not establish agent-specific effects.

Source: [Dharmarajan et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03609-0)

## Related pages
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
